-
Nature: The "regenerating" miracle of pluripotent stem cells
Time of Update: 2022-02-23
For example, iPSC-based therapies could replace neurons that die in Parkinson's disease, retinal tissue damaged by macular degeneration, or could obviate the need for heart transplants .
-
Amgen and Arrakis Therapeutics collaborate to develop small molecules to target RNA degradation
Time of Update: 2022-02-23
On January 11, 2022, Amgen and Arrakis Therapeutics announced a research collaboration to discover and develop RNA-degrading therapeutics for a range of difficult-to-drug targets across multiple therapeutic areas .
-
Successful use of pig hearts in human transplants brings new hope to address shortage of transplanted organs
Time of Update: 2022-02-23
Griffith and their research team have continued to perfect the surgical technique for transplanting pig hearts into non-human primates .
-
The United States will officially implement the rapid testing plan for the new crown, 3 domestic pharmaceutical companies are expected to seize the opportunity
Time of Update: 2022-02-23
According to the latest report from CNBC, the monthly demand for the rapid detection reagents (antigen reagents) sent by the US government to the public for free may reach 2.
-
Gritstone bio's innovative cancer vaccine enters phase 2/3 clinical trial
Time of Update: 2022-02-23
References:[1] Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC).
-
Jiu'an Medical's New Crown Antigen Rapid Detection POC Professional Edition Kit has been authorized for emergency use in the United States
Time of Update: 2022-02-23
S. subsidiary iHealth America's new coronavirus (SARS-CoV-2) antigen rapid detection POC ( PointOfCare) Professional Edition Kit (Colloidal Gold Immunochromatography) received Emergency Use Authorization (EUA) and received an authorization letter from the U.
S. Emergency Use Authorization (EUA) .
-
"Phoenix" reborn!
Time of Update: 2022-02-23
Lost "Phoenix"Lost "Phoenix"The Phoenix study, a double-blind phase III clinical trial, aims to evaluate the efficacy of ibrutinib combined with R-CHOP regimen in newly-treated non-GCB DLBCL patients.
-
Research develops a novel vaccine strategy to effectively prevent SARS-CoV-2 intranasal infection
Time of Update: 2022-02-23
Study shows a combined strategy of intramuscular PD-1-based receptor binding domain DNA vaccine (PD1-RBD-DNA) and intranasal live attenuated influenza vaccine-based vaccine (LAIV-HK68-RBD) Or induce the strongest mucosal broad-spectrum neutralizing antibodies and lung-resident memory CD8 T cells, which may be effective in preventing the nasal infection challenge of live SARS-CoV-2 in two animal models .
-
Valine plays a key role in cancer growth in T-cell acute lymphoblastic leukemia
Time of Update: 2022-02-23
In a new study, researchers from NYU Langone Health have found that an amino acid called valine, a molecular building block of many animal proteins, plays an important role in T-cell acute lymphoblastic leukemia.
-
Positive interim analysis of Keytruda Phase 3 clinical trial to reduce the risk of recurrence after lung cancer surgery
Time of Update: 2022-02-23
The trial met one of its dual primary endpoints in patients with stage IB-IIIA non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, who underwent surgical resection with Keytruda compared with placebo.
-
Red algae extract inhibits virus infection of cells
Time of Update: 2022-02-23
Innovation Connect RussiaA joint team of Russian scientists has found that polysaccharides contained in Pacific red algae can inhibit virus infection of cells, which will help develop new drugs against virus infection .
-
Johnson & Johnson and TRexBio collaborate to develop novel targets for immunological inflammation
Time of Update: 2022-02-23
Article source: Medical Cube InfoAuthor: PickupOn January 6, TRexBio announced a multi-year research collaboration and license agreement with Janssen Pharmaceutica NV, a division of Johnson & Johnson .
-
What new developments have the participating companies such as Amgen brought to the 40th JPM Healthcare Conference?
Time of Update: 2022-02-23
Retrieved January 11, 2022, from https:// -day-2[2] Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics.
-
Perspective Life's New Crown Detection Kit Medical Device Registration Accepted
Time of Update: 2022-02-23
On January 10, Toujing Life announced that the medical device registration of the 2019 new coronavirus nucleic acid detection kit (cartridge fluorescence PCR method) declared by the company was accepted .
-
Genentech reaches nearly $700 million to develop stem cell therapy for common blinding eye disease
Time of Update: 2022-02-23
Lineage Cell Therapeutics announced today that it has entered into an exclusive global collaboration and license agreement with Genentech, a Roche company, to develop and commercialize OpRegen, a retinal pigment epithelial (RPE)-based cell replacement therapy.
-
Genome editing opens up a new field: "gene magic scissors" enter adult vascular epithelial cells for the first time
Time of Update: 2022-02-23
The researchers developed a unique nanoparticle as a vehicle to deliver genome editing tools, including CRISPR-Cas9, into vascular endothelial cells, the cells that form the lining of blood vessels .
-
Triple therapy Kaftrio and ivacaftor approved in EU for children aged 6-11 with cystic fibrosis
Time of Update: 2022-02-23
Vertex recently announced that the European Commission (EC) has approved the label expansion of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) CF patients with at least one F508del mutation in the gene .
-
Science cover report: Injection of mRNA directly generates CAR-T to effectively repair cardiac function
Time of Update: 2022-02-23
In vivo generation of transient FAP CAR-T cells improves cardiac function after injury (Source: Science)It is reported that the researchers are continuing to test this mRNA-based transient CAR-T cell technology, hoping to eventually begin clinical trials .
-
Omicron is more vulnerable to children's vaccine to prevent severe disease still effective
Time of Update: 2022-02-23
Yesterday, Wu Zunyou, chief epidemiologist of the Chinese Center for Disease Control and Prevention, said that previous data showed that the main cause of Omicron is asymptomatic or mild infection.
-
First FDA Approves Innovative Insomnia Therapies Today in 2022
Time of Update: 2022-02-23
▲ Orexin stimulates multiple signaling pathways that promote wakefulness (Image source: Reference [2])Results of the Phase 3 clinical program showed that Quviviq at a dose of 50 mg significantly improved objective measures of sleep onset and sleep maintenance, as well as patient-reported total sleep time, compared with placebo .
